Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets. AOP Orphan will be responsible for the commercialization of AGGRASTAT in the AOP Orphan countries. Under terms of the agreement, AOP Orphan has agreed to specific annual commercial goals for AGGRASTAT. Financial details of the agreement were not disclosed.

"We are pleased to expand our relationship with AOP Orphan to include AGGRASTAT in addition to BRINAVESS," said Karim Lalji, Cardiome's Chief Commercial Officer. "AGGRASTAT is an excellent fit with AOP's established portfolio of cardiovascular products. We are looking forward to working with AOP to sell AGGRASTAT and to implement Cardiome's commercialization strategy for this product."

"We are excited to partner and work with Cardiome to commercialize AGGRASTAT, the second Cardiome product in our cardiovascular portfolio," said Rudolf Widmann, Ph.D., CEO of AOP Orphan. "We are looking forward to selling AGGRASTAT to our existing customer base and to developing new customer relationships which will be key to the future growth of our cardiovascular franchise."

Key AOP Orphan countries for AGGRASTAT include: Austria, Hungary, Switzerland, and other Eastern European states.


Cardiome Pharma Corp.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment